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Several studies indicate that the I domain located in  
the a  chain (CDlla) of leukocyte function-associated  
antigen-1 (LFA-1; CDlla/CD18) plays an essential role in 
ligand recognition. We recently identified three distinct 
epitopes (IdeA, IdeB, and IdeC) within the C D lla  I do­
main, recognized by antibodies that block binding of 
LFA-1 to intercellular adhesion m olecules (ICAM) 1, 2, 
and 3. In the present study, we used a series of human/ 
murine C D lla  I domain chimeras, to localize a fourth I 
domain epitope (IdeD), recognized by three independ­
ently derived anti-CDlla antibodies that selectively  
block the binding of LFA-1 to ICAM-3, but not to ICAM-1. 
The IdeD epitope depended on human C D lla  residues 
Asp182 and Ser184 and was not present in C D llb  or 
C D llc. Although mutation of Asp182 and Ser184 failed to 
abolish ICAM-3 adhesion of LFA-1 transfectants, align­
ment of these residues with the crystal structure of the 
C D lla  I domain suggested that the IdeD epitope is lo­
cated in  close proximity to residues (lie126 and Asn129) 
recently implicated in the ICAM-3 binding site (1). Inter­
estingly, the IdeB and IdeC epitopes appeared to be in  
close proximity of a divalent cation binding pocket 
w ithin the C D lla  I domain that regulates both ICAM-1 
and ICAM-3 adhesion. Taken together, these data indi­
cate that distinct regions of the C D lla  I domain contain  
epitopes for antibodies that either selectively inhibit 
binding of LFA-1 to ICAM-3, or interfere w ith both  
ICAM-1 and ICAM-3 binding of LFA-1.
The leukocyte integrin LFA-11 (CD 11 a/CD 18) is a cell sur­
face receptor that mediates adhesive interactions and signal 
transduction in the immune system (2-5). LFA-1 is expressed 
by leukocytes and belongs to the jS2  family of integrals, in which 
a common p  subunit (CD18) is associated with any of three 
distinct, but structurally homologous, a subunits; a L (C D lla, 
LFA-1), aM (CDllb, Mac-1), and ax (CDllc, pl50, 95) (2), The 
extracellular domain of the LFA-1 a. subunit contains two do­
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mains thought to be of functional significance. These include a 
putative divalent cation binding region, consisting of three 
tandem repeats of an EF-hand motif, also found in other inte­
r n s  (6, 7) and a 200-amino acid inserted or “I” domain (8), 
which is also present in aM, aX) a ls a2> and aE subunits (2, 9). 
The I domain contains sequences homologous to the type A 
domains of von Willebrand factor, cartilage matrix-binding pro­
tein, and complement factor B (8).
LFA-1 is known to recognize three ligands: ICAM-1 (10), 
ICAM-2 (1 1 ), and ICAM-3 (12-14), all of which are members of 
the Ig superfamily, and have five, two, and five Ig-like domains, 
respectively. ICAM-1 is expressed on many cells, including 
lymphocytes and endothelial cells, and its expression is cyto­
kine inducible (15). ICAM-2 is expressed on lymphocytes, en­
dothelial cells, and platelets (16, 17), whereas ICAM-3 is only 
expressed on leukocytes (18). In contrast to ICAM-1 , expression 
of ICAM-2 and -3 is not induced by cytokines (18, 19).
LFA-l-mediated adhesion requires activation of the LFA-1 
molecule (20—22). Activation can be induced by intracellular 
signals generated upon cross-linking of cell surface receptors (T 
cell receptor/CD3) (21 , 22), upon binding of activating anti- 
LFA-1 antibodies (23-27), or divalent cations, such as Mn2+ 
(28). Activation of LFA-1 and subsequent ligand binding is 
thought to result from conformational changes in the a/p het­
erodimer and requires binding of divalent cations, such as 
Mg2+ and Ca2+, an intact cytoskeleton, and a physiological 
temperature (29). While Ca2+ binding supports clustering of 
LFA-1 on the cell surface, presumably resulting in enhanced 
ligand binding avidity, Mg2*1* binding to LFA-1 has been sug­
gested to alter the affinity of LFA-1 for its ligands (28, 30),
Recent findings indicate that the I domains of C D lla, 
C D llb, and CDllc, as well as I domain sequences of the a x and 
a2 chains of /3X class of integrins, are involved in ligand binding. 
Evidence comes from the finding tha t purified aL (CDlla), %  
(CDllb), and a2 I domains directly bind their respective li­
gands, ICAM-1, fibrinogen and iC3b, or collagen (31-33). Sec­
ond, mutation of aspartic acid or threonine residues within the 
I domains of a M, aL, av  and a 2 affects cation binding and 
impairs adhesion (33-37). Furthermore, we identified residues 
lie126 and Asn129 within the C D lla  I domain to be critical for 
adhesion to ICAM-3, but not for ICAM-1 binding, indicating 
tha t the C D lla  I domain contains distinct binding sites for 
different ligands (1 , 27). Finally, most anti-CD lla, CDllb, and 
C D llc  antibodies that block ligand interactions recognize the I 
domain (38-40). Previous investigations have revealed tha t 
anti-human C D lla  antibodies do not cross-react with murine 
LFA-1 , implying that sequences in the I domain important for 
mAb binding can be located by replacing hum an C D lla  se­
quences with the murine homologues (40). Using human/mouse 
I domain mutants in which sequences from the human C D lla
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I domain were substituted into murine I domain residues, we 
recently demonstrated that an ti-C D lla  I domain antibodies 
that inhibit the interaction of LFA-1 with ICAM-1 , -2, and -32 
{e.g. TS1/22, 25.3, and MHM.24) (39, 40), recognized three 
distinct epitopes within the C D lla  I domain (IdeA, residues 
126-129; IdeB, residues 143-148; IdeC, residues 198-204) 
(40).
In the present studies, we identified a fourth epitope within 
the C D lla  I domain (IdeD), tha t is recognized by three anti- 
C D lla  antibodies that selectively inhibit the binding of LFA-1 
to ICAM-3. Alignment of the IdeD epitope with the recently 
solved crystal structure of the C D lla  I domain (41) suggested 
tha t it is located in close proximity to I domain residues He126 
and Asn129, critical for ICAM-3, bu t not ICAM-1 binding of 
LFA-1 (1 ).
EXPERIMENTAL PROCEDURES
Antibodies—A panel of mouse monoclonal antibodies (mAbs) was 
used, MEM-83 (24), YTH81.5 (39, 42), 122.2A5 (39), NKI-L15 (43), and 
NKI-L16 (23) directed against CDlla, MHM.23 (44), KIM185 (26), and 
MEM-48 (27) directed against CD 18, REK-1 directed against ICAM-1 
(27), AZN-IC3.1 directed against ICAM-3,3 and T3b directed against 
CD3 (45).
Generation of C D lla  I  Domain Mutants—The construction of chi­
meric human/mouse CDlla I domain variants (H/M48-H/M54) and the 
generation of the D137A mutant has been described previously (1, 37, 
40). The H/M48-H/M54, D137A, and D239A mutants were generated by 
oligonucleotide-directed mutagenesis using a plasmid containing the 
entire human CDlla chain (pRKLFAam), as a template. After each 
polymerase chain reaction step, clones were checked by sequencing for 
correct incorporation of oligonucleotides.
Expression of C D lla  Mutants in 293 Cells and Immunofluorescence 
Analysis of Transfectants—Chimeric CDlla and wild type CD18 
cDNAs were cloned into the RK 5 and RK 7 expression plasmids and 
transfected into the 293 human kidney adenocarcinoma cell line, using 
a standard calcium phosphate coprecipitation method (46). Transfec­
tion efficiencies ranged from 30 to 70%. Three days after transfection, 
transfectants were harvested by EDTA (5 mM) treatment and expres­
sion of CDlla/CD18 on the transfectants was determined by immuno­
fluorescence. Cells (2  X 105) were incubated for 1 h at 4 °C with 
appropriate dilutions of the different mAbs (2 jig/ml) in Hepes buffer 
(0.02 M Hepes, 0.14 M NaCl, 0,2% glucose, 1 mM MgCl2, and 1 mM  
CaCl2), followed by incubation with fluorescein isothiocyanate-labeled 
goat (Fab^a anti-mouse (Cappel, Inc., West Chester, PA) or anti-rat IgG 
(Caltag, Los Angeles, CA) antibodies, for 1 h at 4 °C. The percentage of 
positive cells was determined by FAC Sc an analysis (Becton Dickin­
son, Mountain View, CA).
Immunoprécipitation of C D lla  Variants Expressed in 293 Cells— 
The method used for immunoprécipitation of C D lla  variants has been 
described in detail elsewhere (37, 40). Briefly, 2 or 3 days after trans­
fection of CDlla chimeras into 293 cells, transfectants were met aboli- 
cally labeled in methionine-free Dulbecco’s modified Eagle’s medium 
with 100 fxCi/ml [35S]methionine for 4-5 h, The medium was removed, 
and the cells were lysed in 1 ml of lysis buffer (1% Nonidet P-40, 10 mM  
Tris-HCl (pH 7.5), 2 mM CaCl2, and 2 mM MgCl2)/10-cm dish. Cell debris 
and nuclei were pelleted, and the supernatant was used for subsequent 
immunoprécipitations. Antibodies (1-2 /xg/immunoprecipitation) were 
incubated with 100 /llI of labeled lysate and 2 jag of rabbit anti-mouse 
IgG (Cappel) for 2 h at room temperature. The antibody/antigen com­
plexes were precipitated using 2 mg of Protein A-Sepharose CL-4B 
beads (Pharmacia Biotech, Inc., Uppsala, Sweden), the beads were 
washed two times in wash buffer (0.5% Nonidet P-40, 0.01% sodium 
dodecyl sulfate (SDS), 400 mM NaCl, 10 mM Tris-HCl (pH 7.5), 2 mM  
CaCl2, 2 mM MgCl2) and resuspended in 30 /nl of 2 X concentrated 
SDS-polyacrylamide gel electrophoresis sample buffer, boiled for 3 min, 
and centrifuged briefly. The clarified sample was then resolved on 6% 
SDS-polyacrylamide gels.
Adhesion Assay—ICAM-1 and ICAM-3 fusion proteins consisting of 
the five domains of ICAM-1 or ICAM-3 fused to a human IgGl Fc 
fragment (ICAM-lFc and ICAM-3Fc, respectively) were isolated from
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F ig . 1. The C D lla  I domain-specific mAbs MEM-83, YTH81.5 
and 122.2A5 selectively inhibit the LFA-l/ICAM-3 interaction.
After activation of LFA-1 with the CD18-activating antibody MEM-48 
(5—20 jtig/ml), the capacity of HSB T cells or 293 cells transfected with 
CD 1 la/CD 18 constructs, to bind purified ICAM-lFc or ICAM-3Fc pro­
teins (300 ng/ml; 50 jul/well) was determined, in the absence of presence 
of mAbs MEM-83, YTH81.5, 122.2A5, or NKI-L15 (CDlla) at 10-50  
/ug/ml. Results are expressed as the mean percentage of adherent cells 
from triplicate wells. One representative experiment out of three is 
shown.
supernatants of L-cell cultures stably transfected with pICAM-lFc and 
pICAM-3Fc, respectively (13, 47). Culture supernatant was purified by 
protein A column affinity chromatography and eluted by 0.01 M Hepes 
buffer at pH 7.0, containing 0.15 M NaCl, 3.5 M MgClrj, and 10% (w/v) 
glycerol. 96-well flat-bottomed plates (Maxisorb, Nunc, Roskilde, 
Denmark) precoated with 4 ¿xg/ml goat anti-human Fc (Jackson Imrnu- 
noresearch Laboratories, Inc.» Westgrove, PA) for 2 h at 37 °C, and 
blocked with 1% bovine serum albumin (Boehringer Mannheim) (1 h at
RT), were coated overnight at 4 °C with ICAM-lFc or ICAM-3Fc pro­
teins (300 ng/ml, 50 ¿ri/well). A stable human LFA-1 transfected 293 cell 
line (293-LFA), or transiently transfected 293 cells (100,000/well or 
200,000/well, respectively), were added in adhesion buffer (0,14 M NaCl, 
0.2% glucose, 0.02 M Hepes, 1 mM CaCl2, 1 mM MgCl2) in  the presence 
of the indicated mAbs (10-50 ¿¿g/ml) and incubated for 1.5 h at 37 °C. 
Nonadherent cells were removed by three washes with adhesion buffer, 
and cell attachment was measured using the PNAG method of Land- 
egren (48) Results are expressed at mean OD405 values of triplicate 
wells, For adhesion of the human T cell line HSB (obtained from ATCC), 
cells (40,000/well) were labeled with G1Cr for 45 min at 37 °C and 
incubated on ICAM-lFc- or ICAM-3Fc-coated plates for 30 min at 37 °C. 
Nonadherent cells were removed by three washes with adhesion buffer, 
adhering cells were lysed with 1% Triton X-100, and radioactivity was 
quantified. Results are expressed as the mean percentage of adhesion of 
triplicate wells.
Proliferation Assay—96 flat-bottomed wells (Maxisorb, Nunc, Rosk­
ilde, Denmark) were coated with suboptimal concentrations of anti-CD3 
antibodies (T3b, 30 ng/ml, 100 /xl/well, 1 h 37 °C), followed by goat 
anti-human Fc (Jackson Immunoresearch Laboratories, Inc.; 4 /xg/ml, 
100 jid/well, 1 h at 37 °C), 1% BSA (100 /jJ/well, 30 min at 37 °C), and 
ICAM-lFc or ICAM-3Fc proteins (300 ng/ml, 50 ¿¿1/well, 1 h at 37 °C). 
Resting peripheral blood lymphocytes obtained by Ficoll-Hypaque den­
sity centrifugation and subsequent depletion of monocytes by adherence 
to plastic, were added (100,000 cells/well) and cultured for 3 days. On 
day 3 cells were pulsed for 16 h with [3H] thymidine (1.52 TBq/mmol, 0.5 
/xCi/well; Amersham, Buckinghamshire, United Kingdom), to measure 
ICAM-1- or ICAM-3-dependent proliferation. To determine whether 
induced proliferation was LFA-1- and ICAM-1- or ICAM-3-specific, cells 
were cultured in the presence of function blocking antibodies at a 
concentration of 10 jug/ml,
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F i g . 2, MEM-83, YTH81.5, and 122.2A5 inhibit ICAM-3-dependent costim ulation of T cells. Resting T cells were plated on ICAM-lFc or 
ICAM-3Fc, together with suboptimal concentrations of coated anti-CD3 antibodies (30 ng/ml; 50 jul/well), in the presence or absence of mAbs 
MEM-83, YTH81.5, 122.2A5, NKI-L15 (CDlla), REK-1 (ICAM-1), or AZN-IC3.1 (ICAM-3), at 10 iigfml. After 3 days of culture, 3H incorporation 
was determined. Results are expressed as the mean counts/min of triplicate wells. Data are representative of three experiments.
l-domain Divalent cation repeats C terminal region Transmembrane domain
1 126 308 431 586 1064 1087 1145
Human CD11a
B IdeA IdeB IdeD IdeC
126 224
hu C D lla  
mu C D lla
IKGN
MKGK
VDLVFLFDGSMSL
VDLVFLFDGSQSL
¡JFDEFQ
DRKDFE
«LDFHKDVMKKLSNTSYQFAAVQFSTSYKTEF
aLEFMKDVMRKLSNTSYQFAAVQFSTDCRTEF
DFB
VFl
DYVK * WKDPDALL 
DYVKGNKNFDVLL
KHVKHML
3SVQFMF
j LTNTFGAINYVATEVFREEL
■j LTNTFRAINYWAHVFKEES
nRTf — - T?J1M\ A
H/M48
H/M49
H/M50
H/M51
H/M52
H/M53
H/M54
D137A ■A
225 308
hu C D lla  GARPDATKVLIIITDGEATDSGNIDAAKDnRYIIGIGKHFQTKESQETLHKFASKPASEFVKILDTFEKLKDLFTELQKKIYV 
mu C D lla  GARPDATKVLVIITDDEASDKGNISAAHDITRYIIGIGKHFVSVQKQKTLHTFASEPVEEFVKILDTFEKLKDLFTDLQRRIYA
D239A ...........................- - a-
F ig . 3. Amino acid sequences of murine and human C D lla  I domains and human/murine substitution mutants. A, schematic 
representation of CDlla with respective locations of the I domain and the putative metal binding (EF-hand) domains. S, in the human/murine 
chimeras (H/M48-54), one to five human residues were substituted for murine residues. In D137A and D239A mutants, aspartic acid residues were 
substituted for alanine.
antibodies that recognize functionally important epitopes 
within the C D lla  I domain, we determined the ability of sev­
eral anti-CD 1 1 a mAbs to selectively inhibit the binding of 
LFA-1 to ICAM-3 (Fig. 1). The capacity of the LFA- 1 -positive T 
cell line HSB and transfected 293 cells (293-LFA-l) to bind 
purified ICAM-1 (ICAM-lFc) or ICAM-3 (ICAM-3Fc) coated 
onto tissue culture plates, in the presence of the anti-CD 1 1 a 
mAbs MEM-83, YTH81.5, 122.2A5, or NKI-L15 was deter­
mined. Activation of LFA-1 by an activating anti-CD 18 mAb 
(MEM-48), induced adhesion of both HSB and 293-LFA-l cells 
to ICAM-lFc and ICAM-3Fc proteins. The anti-CD 11a mAb 
NKI-L15 blocked binding to ICAM-1 as well as ICAM-3 (Fig. 1 ). 
In contrast, the anti-CD 1 1 a mAbs MEM-83, 122.2A5, and 
YTH81.5 blocked only adhesion to ICAM-3 and not to ICAM-1. 
Inhibition of LFA-l/ICAM-3 adhesion by these antibodies was 
also observed when LFA-1 on the HSB cells was activated with 
phorbol 12-myristate 13-acetate or Mn2+ (data not shown), 
MEM-83, YTH8L5, and 122.2A 5 Inhibit ICAM-3-dependent 
Costimulation o f T  Cells—We next determined whether MEM- 
83, YTH81.5, and 122.2A5 interfered with ICAM-3- or ICAM- 
1-dependent costimulation of T cells, Resting peripheral blood
lymphocytes obtained from healthy donors were plated on 
ICAM-lFc or ICAM-3Fc proteins together with suboptimal con­
centrations of coated anti-CD3 antibodies, in the presence of 
MEM-83, YTH81.5, or 122.2A5, or in the presence of blocking 
antibodies directed against LFA-1 , ICAM-1 , or ICAM-3. Fig. 2 
demonstrates tha t although MEM-83, YTH81.5, and 122.2A5 
selectively inhibited LFA-1/1 CAM-3 adhesion, they interfered 
with both ICAM-1 - and ICAM-3-dependent T cell proliferation. 
ICAM-1 - and ICAM-3-dependent proliferation was prevented 
by blocking antibodies against LFA-1 and by antibodies di­
rected against ICAM-1 or ICAM-3, respectively, indicating tha t 
proliferation was LFA-1 - and ICAM-specific. Interestingly, pro­
liferation on ICAM-lFc was also prevented by blocking anti­
bodies directed against ICAM-3, suggesting tha t proliferation 
on ICAM-1 involves LFA-l/ICAM-3 interactions between pro­
liferating cells. These data may indicate tha t MEM-83, 
YTH81.5, and 122.2A5 inhibit proliferation on ICAM-1 Fc, by 
preventing these LFA-l/ICAM-3 interactions.
M apping o f  the Epitope Recognized by MEM-83, YTH81,5, 
and 122.2A5 within the C D lla  I  Domain—MEM-83, YTH81.5, 
and 122.2A5 have previously been shown to bind to the C D lla
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F ig . 4. Immunoprécipitation of human C D lla  variants w ith  
ICAM-3 blocking anti-C D lla monoclonal antibodies MEM-83, 
YTH81.5, and 122.2A5. The human kidney adenocarcinoma cell line 
293 was transfected with plasmids directing the expression of full- 
length human CDlla (CDlla), or human C D lla I domain variants in 
which human CDlla I domain residues were replaced by corresponding 
murine residues (H/M48-H/M54). A diagram listing the mutations 
introduced in each variant is provided in Fig. 3. ICAM-3 blocking 
anti-CDlla mAbs (MEM-83, YTH81.5, 122.2A5) were added to deter­
gent lysates of transfected cells metabolically labeled with [35S]methi­
onine and subjected to immunoprécipitation. MEM-83 is shown in panel 
A , YTH81.5 in panel By and 122.2A5 in panel C.
I domain (24, 39). To localize residues within in the C D lla  I 
domain important for the binding of these mAbs, a panel of 
human/mouse C D lla  chimeras (H7M48-54) was used in which 
small clusters of amino acids from murine C D lla  replaced the 
corresponding residues of the hum an C D lla  I domain (37, 40). 
A diagram of the chimeric gene products is provided in  Fig. 3.
To identify residues within the C D lla  I domain critical for 
binding of ICAM-3 blocking C D lla  antibodies, we determined 
the ability of MEM-83, 122.2A5 and YTH81.5 to immunopre- 
cipitate chimeric C D lla  proteins from transiently  transfected 
293 cells. The MEM-83, 122.2A5, and YTH81.5 antibodies all 
readily immunoprecipitated H/M53, H/M52, and H/M54 pro­
teins (Fig. 4), showing tha t these antibodies did not bind to the 
previously identified IdeA, IdeB, or IdeC epitopes within the  
C D lla  I domain (40). In contrast, the ICAM-3 blocking anti­
bodies were unable to immunoprecipitate the H/M48 protein, 
suggesting th a t antibody binding depended on Asp182 and 
Ser184 residues, replaced by Thr and Leu, respectively, in the 
H/M48 chimera. The H/M48 mutation did not simply inhibit
T able I
LFA-1 epitope expression on human / mouse I  domain mutants
Summary of reactivity of anti-CDlla mAbs on 293 transfectants, as 
determined by immunofluorescence flow cytometry. 293-cells were 
transfected with CD 18 alone (293-mock), with CD18 and C D lla  
(CDlla), or with human/mouse chimeric C D lla constructs and CD 18 
(H/M48-H/M54). + represents positive staining of 30 -60% of the trans­
fected cells, — represents no significant staining (0-9% of transfected 
cells, not higher than the negative control).
Celia
mAb
MHM.23 NKI-L16 MEM-83 YTH81.5 122.2A5
293-mock — , — — — —
C D lla + + + + +
H/M48 + + — — —
H/M49 + + +
H/M50 + ■f +
H/M51 + -j- + ~b +
H/M52 + + +
H/M53 + +
H/M54 + + + + +
antibody binding by disrupting the overall conformation of 
C D lla , since monoclonal antibodies recognizing the IdeA, 
IdeB, or IdeC epitopes were still able to bind the H/M48 protein 
(40). Thus, H/M48 appeared to define a new epitope recognized 
by several independently isolated monoclonal antibodies.
Since we observed some reduced immunoprécipitation of the 
H/M50 chimera by 122.2A5, we investigated the ability of h u ­
m an CD 18 to form a heterodimeric complex w ith  chimeric 
C D lla , to verify the conformational integrity of the H/M chi­
meras. In these experiments full-length chimeric C D lla  v a ri­
ants were co-transfected with wild type hum an CD 18 into 293 
cells and transfectants were assayed for antibody binding by 
fluorescence-activated cell sorter analysis. Co-expression of 
CD 18 with all C D lla  variants was detected on the cell surface 
(Table I), suggesting th a t the C D lla  I domain m utations pre­
served the structural elements required for heterodim er form a­
tion and export to the cell surface. Another indication for the 
conformational integrity of the H/M variants was provided by 
binding of a murine antibody to hum an CD 18 (MHM.23), th a t 
recognizes an epitope critically dependent on a//3 association of 
C D lla  and CD 18 (44, 49). The observation th a t  MHM.23 
bound all of the I domain variants examined (Table I) provided 
further data  th a t the I domain variants used for epitope m ap­
ping studies did not interfere with structural features required 
for hetero dimer formation. Similarly, the binding of the NKI- 
L16 mAb (C D lla) to the conformation-sensitive L16 epitope 
(23) located outside the C D lla  I domain (37, 50), provided 
additional evidence th a t m utations in the C D lla  I domain do 
not change the overall conformation o fC D lla .  In  contrast to 
the immunoprécipitation studies, mAb 122.2A5 readily bound 
the H/M50 chimera when complexed with CD 18 (Table I), sug­
gesting th a t residues m utated in H/M50 do not directly con­
tribute to the 122.2A5 epitope, but ra th e r affect antibody bind­
ing by inducing subtle conformational changes in C D lla , 
which are not apparent in the CDlla/CD18 heterodimer. To­
gether, these studies demonstrate th a t antibodies tha t selec­
tively inhibit the LFA-l/ICAM-3 interaction, recognize a novel 
epitope w ithin the C D lla  I domain, term ed IdeD, dependent on 
residues Asp182-S e r184.
S p a tia l  Relationship  between C D l l a  I  D om ain  R esidues In­
volved in LFA-1 A ntibody a n d  L igand B inding—Recently, the 
crystal structure of the I domain of the LFA-1 a chain (C D lla ) 
has been elucidated (41). The C D lla  I domain comprises four 
parallel j3 strands C/31-/34) and one short anti-parallel /3 s tran d  
(132'), surrounded by seven a  helices (al-o:7). A single cation 
binding pocket or m etal ion-dependent adhesion site (MIDAS) 
(36), consisting of five cation coordinating residues, is located
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Fig. 5, Adhesion of C D lla  I domain mutants to ICAM-1 and ICAM-3. The capacity of 293 cells transfected with chimeric CDlla and wild 
type CD18 to bind ICAM-lFc or ICAM-3Fc was determined, in the presence of the activating CD18 mAb KIM185 (5-10 jug/ml). A, 293-cells were 
transfected with CD 18 alone (293-mock), with CD 18 and CDlla (CDlla), or with human/mouse chimeric CDlla constructs and CD 18 (H/M48 and 
H/M53). B, the capacity of 293 cells cotransfected with CD 18 and CDlla point mutants D137A or D239A, to bind to ICAM-lFc or ICAM-3Fc was 
determined in the same experiment. Results are expressed as the mean OD405 from triplicate wells. One representative experiment out of three 
is shown,
a t the top of the j3 sheet on the surface of the 1 domain (41), 
Residues important for LFA-1 -ligand and antibody binding 
(Fig. 6) were aligned with the C D lla  I  domain crystal struc­
ture, to analyze their spatial organization. Interestingly, two of 
the epitopes (IdeB and IdeC) recognized by mAbs that block 
LFA-1 binding to ICAM-1 , -2, and -32 (39, 40) are located in 
helical domains adjacent to the cation binding site, This cation 
binding site controls both ICAM-1 and ICAM-3 adhesion, since 
mutation of the cation coordinating residues Asp137 and Asp239 
into alanine (D137A, D239A), abolished LFA-1 binding to both 
ICAM-1 and ICAM-3 (1 , Fig. 5). The third epitope (IdeA), rec­
ognized by mAbs that block ICAM-1, -2, and -3 binding2 (39, 
40), is spatially distinct from the IdeB and IdeC epitopes and is 
located at the N terminus of the first /3 strand of the C D lla  I 
domain (j31). In Fig. 6, only the fourth residue of the IdeA 
epitope is depicted, since the first three residues were not 
included in the C D lla  I domain crystal. Recently, we showed 
th a t replacement of lie126 and Asn129 by Met and Lys, respec­
tively, selectively destroyed antibody binding to the IdeA 
epitope and the ability of the H/M53 chimera to bind to 
ICAM-3, while preserving its ability to bind ICAM-1 (Ref. 1 ; 
Fig. 5). Thus, residues critical for ICAM-3 binding appear to 
coincide with the IdeA epitope located at the very beginning of 
the first j3 strand of the C D lla  I domain (/31). Finally, residues 
Asp182 and Ser184 in the a2 helix define the IdeD epitope, 
recognized by antibodies that selectively inhibit LFA-1 binding 
to ICAM-3. Disruption of the IdeD epitope (H/M48) did not 
result in reduced binding to ICAM-3 (Ref 1; Fig. 5), indicating 
tha t the IdeD epitope does not contain residues directly in­
volved in ICAM-3 binding. However, although Asp182 and 
Ser184 are located a considerable distance away from the IdeA 
epitope in primary structure, when placed on the C D lla  I 
domain crystal, the IdeD epitope appears to be in close prox­
imity of the IdeA epitope and residues critical for ICAM-3 
binding, at the N terminus of the first j3 strand of the C D lla  I 
domain (/31). Thus, regions important for ICAM-3 binding and 
binding of mAbs that block ICAM-3 binding to C D lla  appear to 
be located in similar parts of the molecule.
DISCUSSION
We have demonstrated that the C D lla  I domain-specific 
antibodies MEM-83, YTH81.5 and 122.2A5 th a t selectively in­
hibit the interaction of LFA-1 with ICAM-3 (27, 39), bind to a 
novel epitope (IdeD) in the I domain of C D lla . This is distinct 
from the previously identified IdeA, IdeB and IdeC epitopes,
Fig. 6. Ribbon representation of C D lla  I domain based on 
coordinates provided by Leahy et ah (41). Epitopes recognized by 
antibodies to CDlla (IdeA, IdeB, IdeC, and IdeD) have been aligned 
with the C D lla sequence and are shown as black ribbon or tube. Mn2+ 
ion (black sphere), and N and C termini have also been labeled. Ribbon 
diagram was drawn using the MIDAS program (University of Califor­
nia, San Francisco). Positions corresponding to the IdeB epitope (resi­
dues 143-148), the IdeC epitope (residues 198-204), and the IdeD 
epitope (Asp182 and Ser184) are indicated. Of the IdeA epitope (Ile12ts and 
Asn129) only the fourth residue (Asn129) is indicated, since the first three 
residues were not included in the CDlla I domain crystal.
recognized by antibodies tha t block LFA-1 binding to ICAM-1, 
-2 and -32 (39, 40). Site-directed mutagenesis demonstrated 
th a t the IdeD epitope comprises amino acids Asp182 and S er184, 
although mutation of these residues failed to inhibit the bind­
ing of LFA-1 to ICAM-3. Thus antibody binding to the IdeD 
epitope appears to interfere with ICAM-3 binding by steric 
hindrance rather than by competitive binding to the ligand 
binding site. Placement of the IdeD epitope on the crystal 
structure of the C D lla  I domain (41) suggested that the IdeD 
epitope was located in close proximity to residues recently 
identified as being critical for ICAM-3 binding to LFA-1 (1 ).
Interestingly, residues critical for ICAM-3 binding (lie126 
and Asn129) and the IdeD epitope are both unique to hum an  
C D lla  and are not found in CD l ib  or CD 1 1 c, suggesting th a t 
these represent a structural feature (i.e. all or part of a ligand 
binding domain) unique to LFA-1 . These data are consistent
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with earlier observations tha t MEM-83, YTH81.5, and 122.2A5 
failed to cross-re act with CD l i b  or CD 1 1 c (39). Although 
MEM-83, YTH81.5, and 122.2A5 all bind the IdeD epitope, they 
show some functional differences, since MEM-83 can activate 
LFA-l-mediated adhesion to ICAM-1 (24,27), whereas 122.2A5 
and YTH81.5 cannot (39). This suggests th a t MEM-83 can 
induce or stabilize an active ICAM-1 binding conformation of 
LFA-1 (24). Surprisingly, we observed th a t MEM-83, YTH81.5 
and 122,2 A5, as well as blocking antibodies directed against 
ICAM-3, inhibited ICAM-1-induced T cell proliferation. These 
data suggest th a t although T cell costimulation in this system 
is dependent on engagement of LFA-1 by coated ICAM-1 , opti­
mal proliferation may require LFA-l/ICAM-3 interactions be­
tween proliferating cells, which are prevented by IdeD-specific 
anti-C D lla antibodies. We previously reported th a t MEM-83 
(27), as well as YTH81.5 and 122.2A5 (data not shown), are 
potent inhibitors of the LFA-IflCAM-2 interaction, suggesting 
that residues critical for ICAM-2 and ICAM-3 binding may be 
located in close proximity. It will therefore be im portant to 
determine whether the sequence th a t has been shown to be 
essential for ICAM-3 binding, is also involved in LFA-1 binding 
to ICAM-2.
In addition to ligand-specific sequences, the LFA-1 1 domain 
contains conserved sequences required for adhesion of LFA-1 to 
all ligands. Interestingly, when aligned with the C D lla  I do­
main structure (41), two of the recently identified C D lla  I 
domain epitopes (IdeB and IdeC) recognized by antibodies th a t 
block ICAM-1 , ICAM-2, and ICAM-3 binding2 (39, 40) were 
located in close proximity to the divalent cation binding pocket, 
or MIDAS motif (36). Residues within this motif (Asp137, 
Asp239, and T hr206) have been implicated in cation binding (34) 
and/or ligand binding of the I domain containing integrins
Mac-1 , a2p lf «101, and LFA-1 (Refs. 1, 33-37, and 51; Fig. 5). In 
the C D lla  I domain crystal structure, a Mn2+ ion is coordi­
nated by five cation coordinating residues. A critical acidic 
glutamate residue (E) within the integrin binding motif 
I/L-E-T-P/S-L in  the first Ig-like domains of ICAM-1 , -2, or -3 
(47, 52) may provide the sixth cation coordinating residue in  
vivo, implying a role for metal ions in the stabilization of 
LFA-1 /ligand interactions (36, 53). In addition, residues in 
proximity of the divalent cation binding pocket (Met140, Glu146, 
Thr243, and Ser245) were shown to be critical for binding of 
LFA-1 to ICAM-1 (50), underlining the importance of this I 
domain region in LFA-1/ligand interactions. It is tempting to 
speculate th a t antibodies recognizing the IdeB and IdeC 
epitopes interfere with LFA-1 function by inhibiting actual 
ligand binding residues in this area, or by altering the confor­
mation of such residues. Alternatively, these antibodies may 
affect adhesion by altering the conformation of residues in ­
volved in cation coordination, resulting in destabilization of the 
cation binding site.
Our data  identify two distinct regions w ithin the C D lla  I 
domain th a t contain residues critical for ICAM-3 binding: the 
region involved in cation binding and the region defined by the  
IdeA epitope a t the other side of the I  domain. These regions 
may both contain actual contact sites for ICAM-3, implying 
that ICAM-3 contacts a relatively large binding face on LFA-1 . 
However, i t  is also possible th a t mutations introduced in either 
one of these regions induce subtle conformational changes in 
the C D lla  I domain, which reduce binding to ICAM-3. As yet 
we cannot distinguish between these possibilities.
In conclusion, our data  indicate th a t distinct regions of the 
C D lla  I domain contain epitopes recognized by antibodies th a t 
either selectively inhibit binding of LFA-1 to ICAM-3, or inhibit 
both ICAM-1 and ICAM-3 adhesion of LFA-1 . These antibodies 
may inhibit LFA-1 function by either interfering with ligand-
specific sequences, or conserved domains within the C D lla  
domain, th a t are required for binding of LFA-1 to both ICAM-1 
and ICAM-3. The challenge of future research will be to under­
stand how during integrin activation subtle conformational 
changes within the a  and subunits lead to exposure of these 
functionally im portant domains and subsequent ligand b ind­
ing. The ability of antibodies to selectively inhibit LFA-1-ligand 
binding might find utility in the development of im mune re ­
sponse and inflammatory response modulators. Moreover, 
these results suggest th a t the  capacity of an ti-C D lla  antbodies 
to interfere with leukocyte function {e.g. antigen presentation, 
cytotoxic killing, and B cell activation), historically attributed  
to disruption of LFA-l/ICAM-1 interactions, should be re-ex­
amined to evaluate the possible role of ICAM-2 and  ICAM-3.
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